ProKidney Corp. (BMV:PROK)

Mexico flag Mexico · Delayed Price · Currency is MXN
46.33
+3.63 (8.50%)
At close: Dec 4, 2025
28.69%
Market Cap6.03B
Revenue (ttm)13.65M
Net Income (ttm)-1.30B
Shares Outn/a
EPS (ttm)-9.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,508
Average Volume24,747
Open45.40
Previous Close42.70
Day's Range45.40 - 46.33
52-Week Range12.18 - 132.00
Betan/a
RSI41.03
Earnings DateNov 12, 2025

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 204
Stock Exchange Mexican Stock Exchange
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.